Sagent Pharmaceuticals, Inc. has launched oxacillin for injection, USP, in three latex-free, preservative-free vial presentations. According to IMS data for the twelve-months ended May 2012, the US market for Oxacillin approximated $29 million. As with all products in Sagent's portfolio, Oxacillin features the company's PreventIV MeasuresSM packaging and labelling designed to aid in the reduction of medication errors.

Oxacillin for injection, USP is a semisynthetic penicillin indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug.

Sagent Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.